FORE Biotherapeutics: $38 Million Series D-2 Raised For Advancement Of Plixorafenib
By Amit Chowdhry ● May 23, 2025
FORE Biotherapeutics, a registration-stage biotherapeutics company focused on developing targeted therapies to treat cancer patients, announced a $38 million Series D-2 financing. For this initial close of the Series D-2, leading healthcare-dedicated investors participated, such as SR One, Medicxi, OrbiMed, HBM Healthcare Investments, Wellington Management, Novartis Venture Fund, Cormorant Asset Management, and 3B Future Health Fund.